MetaCap

Greenwich LifeSciences (GLSI) vs ARS Pharmaceuticals (SPRY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Greenwich LifeSciences (GLSI) has outperformed ARS Pharmaceuticals (SPRY) over the past year, gaining 136.2% versus a loss of 61.0%. Over five years, GLSI leads with a -41.8% price change compared with -58.8% for SPRY. ARS Pharmaceuticals is the larger company by market cap ($297.6 million vs $282.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GLSI+136.20%SPRY-61.00%
+331%+123%-84%
Nov 21, 20251 yearNov 20, 2026
GLSI-44.75%SPRY-63.99%
+131%+21%-89%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GLSI versus SPRY key metrics
MetricGLSISPRY
Share price$19.25$2.96
Market cap$282.56M$297.56M
1-day change-2.73%-11.90%
YTD return-8.38%-74.59%
1-year return+136.20%-61.00%
5-year return-41.84%-58.83%
EPS (TTM)$-1.63$-2.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$84.28M
Revenue growth (YoY)—-5.46%
Net income (latest FY)$-19.36M$-171.30M
Operating margin—-212.92%
Net margin—-203.25%
52-week high$34.10$13.15
52-week low$7.78$2.44
Distance from 52-week high-43.55%-77.49%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+198.70%+474.32%
Average volume160.76K1.83M
Shares outstanding14.68M100.53M
Employees—203
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GLSI has outperformed SPRY by 197.2 percentage points over the past year.

About Greenwich LifeSciences

GLSI stock →

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.

Health Care · Biotechnology: Pharmaceutical Preparations

About ARS Pharmaceuticals

SPRY stock →

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.

Health Care · Biotechnology: Pharmaceutical Preparations · 203 employees

GLSI vs SPRY FAQ

Which is bigger, Greenwich LifeSciences or ARS Pharmaceuticals?

ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $297.56M compared with $282.56M for Greenwich LifeSciences (GLSI).

Which stock has performed better over the past year, GLSI or SPRY?

GLSI returned +136.20% over the past 12 months, compared with -61.00% for SPRY (price return, excluding dividends). Past performance does not predict future results.

Are Greenwich LifeSciences and ARS Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons